NIBRT Scientist Leads Program for Single-Cell Analysis Research
Colin Clarke, from the National Institute for Bioprocessing Research and Training, will lead a four-year European Industrial Doctoral Program for enhancing upstream biopharmaceutical manufacturing process development through single cell analysis.
The National Institute for Bioprocessing Research and Training (NIBRT) announced in a Sept. 17, 2018 press release that a four-year doctoral training and research program focusing on enhancing upstream biopharmaceutical manufacturing process development through single-cell analysis would be led by its one of its researchers, Dr. Colin Clarke. The competitive European Industrial Doctorate (EID) program is funded by the Marie SkÅodowska-Curie Actions program of Horizon 2020. Clarke ‘s team will collaborate with scientists across Europe in the €2.9 million (USD 3.4 million) project, which will begin in 2019.
Overcoming the inherent heterogeneity of cells grown in vitro to deliver effective, uniform, and safe biological medicines is one of the most significant challenges faced by the industry today, according to the press release. The STACCATO research program will develop single-cell analysis methods to characterize the molecular heterogeneity of cell populations used in the biopharmaceutical industry.
“We’re delighted that Colin will lead this program to develop the next generation of early-stage researchers. A key feature of STACCATO is collaboration amongst experts in the production of different biopharmaceuticals which provide highly encouraging clinical outcomes,” said Dominic Carolan, NIBRT CEO, in the release.
Source: NIBRT
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
